APA

Kane S. V., Horst S., Sandborn W. J., Becker B., Neis B., Moscandrew M., Hanson K. A., Tremaine W. J., Bruining D. H., Faubion W. A., Pardi D. S., Harmsen W. S., Zinsmeister A. R. & Loftus E. V. (20130503). Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. : Inflammatory bowel diseases.

Chicago

Kane S V, Horst S, Sandborn W J, Becker B, Neis B, Moscandrew M, Hanson K A, Tremaine W J, Bruining D H, Faubion W A, Pardi D S, Harmsen W S, Zinsmeister A R and Loftus E V. 20130503. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. : Inflammatory bowel diseases.

Harvard

Kane S. V., Horst S., Sandborn W. J., Becker B., Neis B., Moscandrew M., Hanson K. A., Tremaine W. J., Bruining D. H., Faubion W. A., Pardi D. S., Harmsen W. S., Zinsmeister A. R. and Loftus E. V. (20130503). Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. : Inflammatory bowel diseases.

MLA

Kane S V, Horst S, Sandborn W J, Becker B, Neis B, Moscandrew M, Hanson K A, Tremaine W J, Bruining D H, Faubion W A, Pardi D S, Harmsen W S, Zinsmeister A R and Loftus E V. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. : Inflammatory bowel diseases. 20130503.